EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy

Milind Y Desai, Iacopo Olivotto, Theodore Abraham, Steven E Nissen, Pablo Garcia-Pavia, Renato D Lopes, Perry M Elliott, Fabio Fernandes, Edileide de Barros Correia, Roberto Barriales-Villa, Esther Zorio, Michael Arad und 13 weitere

JACC · 2025

DOI: 10.1016/j.jacc.2025.08.017 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC, 2025. Verfasst von Milind Y Desai und 24 weiteren Autor:innen. Beteiligte Einrichtung: Hypertrophic Cardiomyopathy Center, Cleveland Clinic, Cleveland, Ohio, USA; Cleveland Clinic Coordinating Center for Clinical Research, Heart Vascula…. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Peptide Fragments, Troponin I, Natriuretic Peptide, Brain. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: No therapy is approved for patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The ODYSSEY-HCM (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy [ODYSSEY-HCM]; NCT05582395) trial, the largest to date in patients with hypertrophic cardiomyopathy (HCM), evaluating the efficacy of mavacamten in symptomatic adults with nHCM, did not demonstrate improvements in its primary endpoints (functional capacity and patient-reported health status). OBJECTIVES: The current exploratory analysis from the ODYSSEY-HCM trial reports the associations between: 1) baseline biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP] and high-sensitivity cardiac troponin I [cTnI]) with clinical, exercise, and echocardiographic characteristics; and 2) comparing changes in these biomarkers from baseline to week 48 between mavacamten and placebo groups. METHODS: Symptomatic nHCM patients were randomized to placebo or mavacamten (starting at 5 mg/d, with titration ranging from 1 to 15 mg, based on left ventricular [LV] ejection fraction). Along with clinical and echocardiographic parameters, NT-proBNP and hs-cTnI were measured for changes from baseline to week 48. RESULTS: Among 580 randomized patients (mean age 56 ± 15 years, 266 [45.9%] women), baseline biomarkers were elevated with median NT-proBNP 917.5 ng/L (IQR: 463-1,725 ng/L) and hs-cTnI of 29.1 ng/L (IQR: 14.4-91.7 ng/L). On multivariable analysis, female sex, body mass index, NYHA functional class, maximal LV wall thickness, left atrial volume index, and E/e' were associated with higher baseline NT-proBNP. Only younger age and LV mass index were associated with higher baseline hs-cTnI level. At week 48, the mavacamten group had a 58% reduction in NT-proBNP (geometric mean ratio: 0.42; 95% CI: 0.37-0.47; P < 0.001) and a 51% reduction in hs-cTnI (geometric mean ratio: 0.49; 95% CI: 0.45-0.53; P < 0.001). No significant change in either biomarker was seen in the placebo group. These reductions occurred early and were maintained through week 48. CONCLUSIONS: Treatment with mavacamten for 48 weeks in nHCM patients was associated with marked biomarker improvements compared with placebo. Whether these changes translate into longer-term adaptive remodeling and improvements in patient-reported health status, exercise capacity, and outcomes remain to be ascertained. (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy [ODYSSEY-HCM]; NCT05582395).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicPeptide FragmentsTroponin INatriuretic Peptide, BrainUracilHumansFemaleMaleBiomarkersMiddle AgedEchocardiographyAgedDouble-Blind MethodAdultTreatment Outcome

Stichwörter der Autor:innen

biomarkersmavacamtennonobstructive HCMrandomized controlled trial

Substanzen

BiomarkersPeptide FragmentsTroponin INatriuretic Peptide, Brainpro-brain natriuretic peptide (1-76)Uracil

Autor:innen und Institutionen

  • Hypertrophic Cardiomyopathy Center, Cleveland Clinic, Cleveland, Ohio, USA; Cleveland Clinic Coordinating Center for Clinical Research, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA. Electron…
  • Department of Cardiology, Meyer Children's Hospital IRCCS, Florence Italy.
  • Department of Cardiology, University of San Francisco, San Francisco, California, USA.
  • Cleveland Clinic Coordinating Center for Clinical Research, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Cardiology, Hospital Universitario Puerta de Hierro, IDIPHISA, CIBERCV, and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.
  • Department of Cardiology, Duke University, Durham, North Carolina, USA.

Förderung

  • Bristol Myers Squibb

Zitieren

APA

Desai, M. Y., Olivotto, I., Abraham, T., Nissen, S. E., Garcia-Pavia, P., Lopes, R. D., Elliott, P. M., Fernandes, F., de Barros Correia, E., Barriales-Villa, R., Zorio, E., Arad, M., Shin, S. H., Verheyen, N., Meder, B., Azevedo, O., Kitaoka, H., Wolski, K., Wang, Q., …, & ODYSSEY-HCM Investigators (2025). Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy. JACC. https://doi.org/10.1016/j.jacc.2025.08.017

Vancouver

Desai MY, Olivotto I, Abraham T, Nissen SE, Garcia-Pavia P, Lopes RD, et al. Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy. JACC. 2025. doi:10.1016/j.jacc.2025.08.017

BibTeX
@article{Desai2025,
  author = {Desai, Milind Y and Olivotto, Iacopo and Abraham, Theodore and Nissen, Steven E and Garcia-Pavia, Pablo and Lopes, Renato D and Elliott, Perry M and Fernandes, Fabio and de Barros Correia, Edileide and Barriales-Villa, Roberto and Zorio, Esther and Arad, Michael and Shin, Sung-Hee and Verheyen, Nicolas and Meder, Benjamin and Azevedo, Olga and Kitaoka, Hiroaki and Wolski, Kathy and Wang, Qiuqing and Suryawanshi, Bharat and Wang, Zhaoqing and Florea, Victoria and Aronson, Ron and Owens, Anjali T and ODYSSEY-HCM Investigators, ODYSSEY-HCM Investigators},
  title = {Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy},
  journal = {JACC},
  year = {2025},
  doi = {10.1016/j.jacc.2025.08.017}
}
Kostenlos starten →